Suppr超能文献

一过性免疫抑制:感染与吉兰-巴雷综合征非典型自身免疫之间的桥梁?

Transient immunosuppression: a bridge between infection and the atypical autoimmunity of Guillain-Barré syndrome?

机构信息

Department of Neurology, Rabin Medical Center, Petah Tiqva, D-Pharm Ltd, Kiryat Weizmann Science Park, Rehovot, Israel.

出版信息

Clin Exp Immunol. 2010 Oct;162(1):32-40. doi: 10.1111/j.1365-2249.2010.04223.x.

Abstract

Guillain-Barré syndrome (GBS) is an acute, usually monophasic, disorder of the peripheral nervous system that is assumed to be of immune-mediated pathogenesis. However, several clinical features and experimental findings of GBS are uncharacteristic for an immune-mediated disorder and set this condition apart from other disorders with a putative immune-mediated pathogenesis. These features include, among others, the monophasic nature of GBS, the lack of response to immunosuppressive (unlike immunomodulatory) therapy, the absence of a typical association with immunogenetic background and the inability to establish a valid and relevant animal model. We suggest a comprehensive hypothesis for the pathogenesis of GBS that is based on the assumption that the condition is due to a transient (or occasionally chronic) immune deficiency, as in most cases GBS follows an infection with pathogens known to induce immunosuppression. Such infections may be followed by breakdown of immune tolerance and induction of an immune attack on peripheral nerves. Mounting of the immune-mediated assault might be triggered either by the same infective pathogen or by secondary infection. Clearance of the infection and resumption of a normal immune response and tolerance eventually terminate the immune-mediated damage to the peripheral nerves and enable recovery. This hypothesis assumes that the entire sequence of events that culminates in GBS is due to transient exogenous factors and excludes a significant role for inherent host susceptibility, which explains the monophasic nature of the disorder.

摘要

格林-巴利综合征(GBS)是一种急性、通常单相的周围神经系统疾病,被认为是免疫介导的发病机制。然而,GBS 的几个临床特征和实验发现与免疫介导的疾病不一致,使这种疾病与其他具有潜在免疫介导发病机制的疾病区分开来。这些特征包括 GBS 的单相性质、对免疫抑制(不同于免疫调节)治疗无反应、缺乏与免疫遗传背景的典型关联以及无法建立有效的相关动物模型。我们提出了一个关于 GBS 发病机制的综合假设,该假设基于这样的假设,即这种情况是由于暂时(或偶尔是慢性)免疫缺陷引起的,因为在大多数情况下,GBS 是在感染已知会引起免疫抑制的病原体之后发生的。此类感染可能随后导致免疫耐受的破坏和对外周神经的免疫攻击。免疫介导的攻击的发生可能是由相同的感染病原体或继发感染触发的。感染的清除和正常免疫反应和耐受性的恢复最终终止对外周神经的免疫介导损伤,并实现恢复。该假设假定导致 GBS 的整个事件序列都归因于短暂的外源性因素,并排除了宿主固有易感性的重要作用,这解释了该疾病的单相性质。

相似文献

1
Transient immunosuppression: a bridge between infection and the atypical autoimmunity of Guillain-Barré syndrome?
Clin Exp Immunol. 2010 Oct;162(1):32-40. doi: 10.1111/j.1365-2249.2010.04223.x.
3
Guillain-barré syndrome: modern theories of etiology.
Curr Allergy Asthma Rep. 2011 Jun;11(3):197-204. doi: 10.1007/s11882-011-0190-y.
5
Role of cytokines and Toll-like receptors in the immunopathogenesis of Guillain-Barré syndrome.
Mediators Inflamm. 2014;2014:758639. doi: 10.1155/2014/758639. Epub 2014 Sep 22.
6
Guillain-Barré syndrome--a classical autoimmune disease triggered by infection or vaccination.
Clin Rev Allergy Immunol. 2012 Apr;42(2):121-30. doi: 10.1007/s12016-010-8213-3.
7
Zika autoimmunity and Guillain-Barré syndrome.
Curr Opin Rheumatol. 2019 Sep;31(5):484-487. doi: 10.1097/BOR.0000000000000629.
8
A review of the role of genetic factors in Guillain-Barré syndrome.
J Mol Neurosci. 2021 May;71(5):902-920. doi: 10.1007/s12031-020-01720-7. Epub 2020 Oct 7.
9
Pathogenesis of Guillain-Barré syndrome.
J Neuroimmunol. 1999 Dec;100(1-2):74-97. doi: 10.1016/s0165-5728(99)00195-2.
10
Abnormality of circulating CD4(+)CD25(+) regulatory T cell in patients with Guillain-Barré syndrome.
J Neuroimmunol. 2007 Dec;192(1-2):206-14. doi: 10.1016/j.jneuroim.2007.09.034. Epub 2007 Nov 13.

引用本文的文献

3
Intracerebral haemorrhage and Guillain-Barré syndrome: an exploration of potential pathophysiology.
BMJ Case Rep. 2021 Aug 3;14(8):e243245. doi: 10.1136/bcr-2021-243245.
5
The clinical characteristics and short-term prognosis in elderly patients with Guillain-Barré syndrome.
Medicine (Baltimore). 2017 Jan;96(1):e5848. doi: 10.1097/MD.0000000000005848.
6
Probiotics as a Potential Alternative for Relieving Peripheral Neuropathies: a Case for Guillain-Barré Syndrome.
Front Microbiol. 2016 Jan 7;6:1497. doi: 10.3389/fmicb.2015.01497. eCollection 2015.
7
Guillain-Barré syndrome and severe infection following chemotherapy for peripheral T-cell lymphoma: A case report.
Oncol Lett. 2014 Dec;8(6):2695-2698. doi: 10.3892/ol.2014.2541. Epub 2014 Sep 16.
8
Broadening the translational immunology landscape.
Clin Exp Immunol. 2012 Dec;170(3):249-53. doi: 10.1111/j.1365-2249.2012.04671.x.
9

本文引用的文献

1
Fisher syndrome and Bickerstaff brainstem encephalitis (Fisher-Bickerstaff syndrome).
J Neuroimmunol. 2009 Oct 30;215(1-2):1-9. doi: 10.1016/j.jneuroim.2009.05.020. Epub 2009 Jul 29.
2
Electrophysiologic and immunopathologic correlates in Guillain-Barré syndrome subtypes.
Expert Rev Neurother. 2009 Jun;9(6):869-84. doi: 10.1586/ern.09.43.
3
Vaccines and Guillain-Barré syndrome.
Drug Saf. 2009;32(4):309-23. doi: 10.2165/00002018-200932040-00005.
4
Guillain-Barré syndrome: an update.
J Clin Neurosci. 2009 Jun;16(6):733-41. doi: 10.1016/j.jocn.2008.08.033. Epub 2009 Apr 7.
5
The T(reg)/Th17 cell balance: a new paradigm for autoimmunity.
Pediatr Res. 2009 May;65(5 Pt 2):26R-31R. doi: 10.1203/PDR.0b013e31819e76c7.
6
Clinical features, pathogenesis, and treatment of Guillain-Barré syndrome.
Lancet Neurol. 2008 Oct;7(10):939-50. doi: 10.1016/S1474-4422(08)70215-1.
7
Susceptibility to Guillain-Barré syndrome is not associated with CD1A and CD1E gene polymorphisms.
J Neuroimmunol. 2008 Dec 15;205(1-2):110-2. doi: 10.1016/j.jneuroim.2008.08.013. Epub 2008 Oct 5.
8
Interplay between effector Th17 and regulatory T cells.
J Clin Immunol. 2008 Nov;28(6):660-70. doi: 10.1007/s10875-008-9239-7. Epub 2008 Sep 23.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验